CN105943603A - Traditional Chinese medicine for preventing and treating senile dementias - Google Patents
Traditional Chinese medicine for preventing and treating senile dementias Download PDFInfo
- Publication number
- CN105943603A CN105943603A CN201610477835.5A CN201610477835A CN105943603A CN 105943603 A CN105943603 A CN 105943603A CN 201610477835 A CN201610477835 A CN 201610477835A CN 105943603 A CN105943603 A CN 105943603A
- Authority
- CN
- China
- Prior art keywords
- parts
- huperzine
- chinese medicine
- ginkgetin
- puerarin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for preventing and treating senile dementias. The traditional Chinese medicine for preventing and treating the senile dementias is prepared from a ginkgo leaf extract containing ginkgetin, a radix salviae miltiorrhizae extract containing tanshinone II A, a radix puerariae extract containing puerarin and a serrate clubmoss herb extract containing huperzine A; active ingredients comprises the following components in parts by weight: 100-500 parts of the ginkgetin, 10-100 parts of the tanshinone II A, 10-100 parts of the puerarin and 1 part of the huperzine A. A traditional Chinese medicinal preparation provided by the invention is prepared from natural Chinese herbal medicines which serve as main raw materials, and through pharmacodynamic tests, is proved, by results, to have effects of resisting ageing, improving memories, and preventing and treating the senile dementias.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation (Chinese medicine composition) preventing and treating senile dementia and preparation method thereof.
Background technology
Along with modern society's growth in the living standard, the average life of people rises year by year, and population in the world senescence phenomenon is severe.
In recent years, various epidemiologies annoying the sickness rate of the healthy of old people, especially senile dementia and constantly rise, and become
One of three big killers for harm senior health and fitness.Senile dementia is that the nervous system of the Progressive symmetric erythrokeratodermia development of a kind of onset concealment moves back
Row disease.Clinical signs be dysmnesia, aphasia, apraxia, agnosia, visual space technical ability infringement, perform dysfunction with
And the feature such as personality and behavior change, along with advancing of disease, patient can gradually lose self care ability, to the individual of patient
Family and society bring white elephant, thus, research and development can have ten with the pharmaceutical preparation of effectively preventing senile dementia
Divide important social meaning and clinical meaning.
Now, treat drug main cholinesterase inhibitor to be had, cerebral vasodilator, the calcium antagonists of senile dementia, prevent A β
Deposit medicine, suppression β, gamma secretase medicine and anti-inflammatory agent and there is the natural component of potential anti-senile dementia effect, although above-mentioned medicine
Thing has shown that certain curative effect in clinical practice, but there is serious inevitable side effect during life-time service.
And the cause of disease of senile dementia and pathogenesis are still not clear, reverse currently without effect method and stop disease progression.
Summary of the invention
The technical problem to be solved in the present invention is that a kind of Chinese medicine (Chinese medicine composition) preventing and treating senile dementia of offer.
For solving the problems referred to above, the present invention provides a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo containing ginkgetin
Extract, the Radix Salviae Miltiorrhizae extract containing tanshinone IIA, the Radix Puerariae extract containing puerarin, Herba Lycopodii serrati containing huperzine A
Extract forms；
The weight of active component is: ginkgetin 100～500 parts, tanshinone IIA 10～100 parts, puerarin 10～100
Part, huperzine A 1 part.
As the improvement of the Chinese medicine preventing and treating senile dementia of the present invention, the weight of active component is: ginkgetin
200～500 parts, tanshinone IIA 10～50 parts, puerarin 10～50 parts, huperzine A 1 part.
As the further improvement of the Chinese medicine preventing and treating senile dementia of the present invention, the weight of active component is: Semen Ginkgo
Leaf flavone 200 parts, tanshinone IIA 30 parts, puerarin 30 parts, huperzine A 1 part.
Further improvement as the Chinese medicine preventing and treating senile dementia of the present invention: ginkgetin in described Folium Ginkgo extract
Weight content is 2～24%；In described Radix Salviae Miltiorrhizae extract, the weight content of tanshinone IIA is 2～80%；In described Radix Puerariae extract
The weight content of puerarin is 2～95%；In described Huperzine Serrate P.E, the weight content of huperzine A is 2～95%.
For example: in Folium Ginkgo extract, the weight content of ginkgetin is 24.0%, the weight of tanshinone IIA in Radix Salviae Miltiorrhizae extract
Content is 9.80%；In Radix Puerariae extract, the weight content of puerarin is 40.0%；The weight of huperzine A in Huperzine Serrate P.E
Content 5.0%.
In the present invention, can be according to routine techniques, with pharmaceutically acceptable carrier or excipient after above-mentioned four kinds of extracts are mixed
Agent is prepared as various dosage form.
In the present invention, the Folium Ginkgo extract containing ginkgetin, the Radix Salviae Miltiorrhizae extract containing tanshinone IIA, containing puerarin
Radix Puerariae extract, Huperzine Serrate P.E containing huperzine A all can be obtained by commercial form, it is also possible to according to known side
Method prepares.
Research shows, cerebrovascular and neural tissue injury are closely related with alzheimer disease.Owing to old people generally exists
The cerebrovasculaies such as hyperlipemia, blood are sticky, cerebral arteriosclerosis, hypertension, the easy pathological changes of cerebral tissue causes senile silly
Slow-witted disease, therefore add some dredging vascellums and nutrition is repaired the active ingredient of nervous tissue and may be delayed and prevent and treat the development of primary disease in good time.
Natural plants exists some have and improve blood circulation and nutrition and repair the natural activity composition of nervous tissue, such as: ginkgetin,
Tanshinone IIA, puerarin etc., so development and utilization pure natural plant extracts health promoting product or the medicine improving senile dementia
Thing becomes a new problem.
The active component of the Chinese medicine preparation of the present invention is extracted by Folium Ginkgo extract, Radix Salviae Miltiorrhizae extract, Radix Puerariae extract and Herba Lycopodii serrati
Active component ginkgetin, tanshinone IIA, puerarin and huperzine A composition, four kinds of mutually coordinated works of active component in thing
With, wherein ginkgetin is monarch drug, is aided with tanshinone IIA, puerarin and huperzine A and reaches to prevent and treat senile dementia.Red
Ginseng and Folium Ginkgo have blood circulation promoting and blood stasis dispelling, promoting QI circulation for relieving depression；Radix Puerariae can increase the blood circulation of local, moistens blood vessels, qualcomm meridian, adjusts smooth gas
Machine；Herba Lycopodii serrati heat-clearing and toxic substances removing, dissipating blood stasis for subsidence of swelling, treatment schizophrenia, myasthenia gravis and senile Memory Impairment are had
Effective or improvement result.Chinese medicine preparation of the present invention is to prepare with natural Chinese medicinal herb for primary raw material, by pharmacodynamics test, result
Confirm its have defying age, improve memory prevent and treat senile dementia effect.
The Chinese medicine preventing and treating senile dementia of the present invention is oral, and dosage such as can refer to Folium Ginkgo extract in treatment dementia
Time dosage (or less than this dosage).
Detailed description of the invention
In following case:
In Folium Ginkgo extract, the weight content of ginkgetin is 24.0%, and in Radix Salviae Miltiorrhizae extract, the weight content of tanshinone IIA is
9.80%；In Radix Puerariae extract, the weight content of puerarin is 40.0%；The weight content 5.0% of huperzine A in Huperzine Serrate P.E.
Above-mentioned Folium Ginkgo extract is such as made by oneself or is purchased from Renhe, Shandong pharmaceutical Co. Ltd；Radix Salviae Miltiorrhizae extract such as make by oneself or
It is purchased from Xi'an Honson Biotechnology Co., Ltd.；Radix Puerariae extract is such as made by oneself or is purchased from Hunan Nature Pharmaceutical Co., Ltd；
Huperzine Serrate P.E is such as made by oneself or is purchased from Hunan Nutramax Inc..
Embodiment 1, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100 parts, tanshinone IIA 10 parts, puerarin 10 parts, huperzine A
1 part.
Embodiment 2, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 200 parts, tanshinone IIA 30 parts, puerarin 30 parts, huperzine A
1 part.
Embodiment 3, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 200 parts, tanshinone IIA 50 parts, puerarin 10 parts, huperzine A
1 part.
Embodiment 4, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 200 parts, tanshinone IIA 10 parts, puerarin 10 parts, huperzine A
1 part.
Embodiment 5, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 200 parts, tanshinone IIA 40 parts, puerarin 40 parts, huperzine A
1 part.
Embodiment 6, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 500 parts, tanshinone IIA 50 parts, puerarin 50 parts, huperzine A
1 part.
Embodiment 7, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 200 parts, tanshinone IIA 10 parts, puerarin 50 parts, huperzine A
1 part.
The production method of various dosage forms is following (utilizing embodiment 1～the Chinese medicine composition of embodiment 7 gained):
1, according to routine techniques, above-mentioned composition is pulverized uniformly mixing, adds cane sugar powder, dextrin, protein sugar, pelletize, be dried,
Granulate, adds magnesium stearate, mixing, and tabletting obtains Compound Tablet.
2, according to routine techniques, first above-mentioned composition is made clear paste, takes sucrose and make syrup, merge with above-mentioned clear paste, stir evenly,
Cooling；Taking Mentholum, benzoic acid is received, and essence is appropriate, after dissolving with 70% ethanol, adds in above-mentioned medicinal liquid, stirs evenly, and stands,
Filter, embedding, sterilizing, obtain oral liquid.
3, according to routine techniques, first above-mentioned composition is pulverized uniform mixing, adds dextrin, then through pelletizing, dry, granulate
It is distributed into bag and becomes granule.
4, according to routine techniques, first raw material pulverizing is uniformly mixed, make granule, be dried the most again, granulate, load capsule,
Obtain capsule.
In order to compare the activity advantage of the present invention, the present invention has also carried out the performance detection of comparative example in experimentation.
Comparative example 1, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing huperzine
The Huperzine Serrate P.E composition of first；
The weight of active component is: ginkgetin 120 parts, huperzine A 1 part.
Comparative example 2, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Huperzine Serrate P.E composition containing huperzine A；
The weight of active component is: ginkgetin 100 parts, tanshinone IIA 20 parts, huperzine A 1 part.
Comparative example 3, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Puerariae
The Radix Puerariae extract of element, the Huperzine Serrate P.E composition containing huperzine A；
The weight of active component is: ginkgetin 100 parts, puerarin 20 parts, huperzine A 1 part.
Comparative example 4, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, total containing Radix Ginseng
The Radix Ginseng extract of Saponin, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100 parts, Radix Ginseng total saponins 10 parts, puerarin 10 parts, huperzine A
1 part.
Comparative example 5, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing Radix Panacis Quinquefolii
The Radix Panacis Quinquefolii extract of Total saponin, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100 parts, total panaquilon 10 parts, puerarin 10 parts, Shi Shan
Alkali first 1 part.
Comparative example 6, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing TANSHINONES
The Radix Salviae Miltiorrhizae extract of II A, the Rhizoma Curcumae Longae extract containing curcumin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100 parts, tanshinone IIA 10 parts, curcumin 10 parts, huperzine A
1 part.
Comparative example 7, a kind of Chinese medicine preventing and treating senile dementia, by the Folium Ginkgo extract containing ginkgetin, containing TANSHINONES
The Radix Salviae Miltiorrhizae extract of II A, the Radix Polygoni Multiflori extract containing stilbene glucoside, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100 parts, tanshinone IIA 10 parts, stilbene glucoside 10 parts, Shi Shan
Alkali first 1 part.
Experiment, pharmacodynamic study
(buy from Central South University Hunan refined medical college Experimental Animal Center) as laboratory animal with Kunming mouse (20 ± 2g), with existing
Having medicine Folium Ginkgo and Huperzine-A Tablets, Tests for Uniformity is positive control medicine group, by body weight, sex difference, is randomly divided into blank group, mould
Type group, Folium Ginkgo group, huperzine A group, embodiment of the present invention 1-7 medicine group and comparative example 1-7 contrast groups, often group 10.
D-galactose injection is used to set up aging model.Blank group does not give any medicine, first 6 week every day nape subcutaneous injection physiology
Saline 0.5mL/20g, also gives normal saline after 6 weeks；Model group is in first 6 week every day of nape subcutaneous injection 5%D-galactose
0.5mL/20g, gave normal saline after 6 weeks.Remaining all starts nape subcutaneous injection 5%D-galactose every day in first 6 weeks in experiment
0.5mL/20g, embodiment of the present invention 1-7 medicine group and comparative example 1-7 group gavage every day (with huperzine A cubage) after 6 weeks
4.0 μ g/kg medicines of the present invention, Folium Ginkgo group gavage 2.4mg/kg every day control drug (calculates with flavonoid of ginkgo biloba), stone
Shan Jianjia group gavage every day 8.0 μ g/kg Huperzine-A Tablets, Tests for Uniformity (with huperzine A cubage).
The passive avoidance ability of test mice: keep away camera bellows and be made up of light and shade two Room that size is identical, bright room is monitoring room, darkroom
For energising room, between two Room, there is an archway.The electric filament lamp of bright room 1 60W of overhung.By interval copper wire bottom darkroom
Composition, logical 36V voltage, after experiment starts, it is first shut off the power supply that shocks by electricity, mice is put into monitoring case facing away from passage, be allowed to certainly
By movable 5min so that it is be familiar with environment.Subsequently, carry out Memory acquisition training, open electric shock switch by mice back to hole, little
Mus, because entering darkroom addicted to dark habit, after being shocked by electricity, flees from darkroom immediately.After 24h, again test, by mice again
Putting into monitoring room, the time that mice enters darkroom the 1st time is incubation period, and the number of times that in 5min, mice enters is errors number.Often
Be spaced two hours, replication totally three times, calculate meansigma methods, result such as following table, test result indicate that, mice give tested
After medicine, medicine group of the present invention all has the effect of the passive avoidance errors number reducing exhausted mining areas with control drug group；Its
Middle medicine group of the present invention is better than control drug group and comparative example group.
Table 1, each group mice passive avoidance ability compare
Note: compare with blank group, △ P ＜ 0.05；
Compare with model group, #P ＜ 0.05；
Compare with huperzine A group, * P ＜ 0.05.
Mice Jumping test is tested: will adapt to 5min, then logical upper 36V alternating current in animal placing response case, animal is stung
After Jiing, reaction is to immediately jump on platform, and majority may jump on the copper grid of energising again or repeatedly, after being shocked by electricity, the soonest
On speed rebound platform, so train 5min.After 24h, retest, for memory retention test, jump off for the 1st time platform time
Between be designated as incubation period, the number of times jumped off in 5min is errors number.At interval of two hours, replication totally three times, calculate average
Value, result such as following table, test result indicate that, medicine group of the present invention all has the diving tower reducing exhausted mining areas with control drug group
The effect of errors number；Medicine group the most of the present invention is better than control drug group and comparative example group.
Table 2, each group mice diving tower ability compare
Note: compare with blank group, △ P ＜ 0.05；
Compare with model group, #P ＜ 0.05；
Compare with huperzine A group, * P ＜ 0.05.
Finally, in addition it is also necessary to be only several specific embodiments of the present invention it is noted that listed above.Obviously, the present invention is not
It is limited to above example, it is also possible to have many deformation.Those of ordinary skill in the art directly can lead from present disclosure
The all deformation gone out or associate, are all considered as protection scope of the present invention.
Claims (7)
1. prevent and treat the Chinese medicine of senile dementia, it is characterised in that: by the Folium Ginkgo extract containing ginkgetin, containing Radix Salviae Miltiorrhizae
The Radix Salviae Miltiorrhizae extract of ketone II A, the Radix Puerariae extract containing puerarin, containing huperzine A Huperzine Serrate P.E composition；
The weight of active component is: ginkgetin 100～500 parts, tanshinone IIA 10～100 parts, puerarin 10～100
Part, huperzine A 1 part.
The Chinese medicine preventing and treating senile dementia the most according to claim 1, it is characterised in that the weight portion of described active component
Proportioning is:
Ginkgetin 200～500 parts, tanshinone IIA 10～50 parts, puerarin 10～50 parts, huperzine A 1 part.
The Chinese medicine preventing and treating senile dementia the most according to claim 2, it is characterised in that:
The weight of described active component is: Folium Ginkgo flavone 200 parts, tanshinone IIA 30 parts, puerarin 30 parts, stone
China fir alkali first 1 part.
4. according to the arbitrary described Chinese medicine preventing and treating senile dementia of claims 1 to 3, it is characterised in that:
In described Folium Ginkgo extract, the weight content of ginkgetin is 2～24%.
5. according to the arbitrary described Chinese medicine preventing and treating senile dementia of claims 1 to 3, it is characterised in that:
In described Radix Salviae Miltiorrhizae extract, the weight content of tanshinone IIA is 2～80%.
6. according to the arbitrary described Chinese medicine preventing and treating senile dementia of claims 1 to 3, it is characterised in that:
In described Radix Puerariae extract, the weight content of puerarin is 2～95%.
7. according to the arbitrary described Chinese medicine preventing and treating senile dementia of claims 1 to 3, it is characterised in that:
In described Huperzine Serrate P.E, the weight content of huperzine A is 2～95%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610477835.5A CN105943603A (en) | 2016-06-27 | 2016-06-27 | Traditional Chinese medicine for preventing and treating senile dementias |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610477835.5A CN105943603A (en) | 2016-06-27 | 2016-06-27 | Traditional Chinese medicine for preventing and treating senile dementias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943603A true CN105943603A (en) | 2016-09-21 |
Family
ID=56905081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610477835.5A Pending CN105943603A (en) | 2016-06-27 | 2016-06-27 | Traditional Chinese medicine for preventing and treating senile dementias |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943603A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356113A (en) * | 2000-11-28 | 2002-07-03 | 袁曙光 | Process for preparing Chinese medicine to treat cardiovascular and cerebrovascular diseases |
| CN1557307A (en) * | 2004-01-29 | 2004-12-29 | 任连坤 | Natural composite preparation for protecting and improving cerebral and heart function and its preparation method |
| CN104548020A (en) * | 2014-12-31 | 2015-04-29 | 东莞市智健医疗科技有限公司 | Application of medicine composition in preparing medicine curing senile dementia |
-
2016
- 2016-06-27 CN CN201610477835.5A patent/CN105943603A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1356113A (en) * | 2000-11-28 | 2002-07-03 | 袁曙光 | Process for preparing Chinese medicine to treat cardiovascular and cerebrovascular diseases |
| CN1557307A (en) * | 2004-01-29 | 2004-12-29 | 任连坤 | Natural composite preparation for protecting and improving cerebral and heart function and its preparation method |
| CN104548020A (en) * | 2014-12-31 | 2015-04-29 | 东莞市智健医疗科技有限公司 | Application of medicine composition in preparing medicine curing senile dementia |
Non-Patent Citations (2)
| Title |
|---|
| 俞丽霞: "《中药药理学》", 31 December 2012, 浙江大学出版社 * |
| 王德隆 等: "《常见慢性病预防与控制》", 31 December 2014, 河北科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Antidepressant active ingredients from herbs and nutraceuticals used in TCM: pharmacological mechanisms and prospects for drug discovery | |
| Huang et al. | The immunopharmaceutical effects and mechanisms of herb medicine | |
| Xiao et al. | Review of the use of botanicals for epilepsy in complementary medical systems—Traditional Chinese Medicine | |
| Mansoori et al. | A randomized, double-blind, placebo-controlled study of safety of the adjunctive saffron on sexual dysfunction induced by a selective serotonin reuptake inhibitor | |
| Debnath et al. | An experimental evaluation of anti-stress effects of Terminalia chebula | |
| Zhang et al. | Botanicals as modulators of depression and mechanisms involved | |
| CN105943888B (en) | Traditional Chinese medicine composition for improving memory and mild cognitive impairment and preparation method thereof | |
| KR20100091206A (en) | Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression | |
| Wu et al. | Research progress on the treatment of epilepsy with traditional Chinese medicine | |
| CN101301357B (en) | Use of schisandra chinensis extract in anti-depression medicament | |
| CN106668564A (en) | Natural pharmaceutical composition capable of improving memory function | |
| Sharma et al. | A systematic updated review of scientifically tested selected plants used for anxiety disorders | |
| KR101256210B1 (en) | Pharmaceutical Compositions for Treating Anxiety | |
| CN105943603A (en) | Traditional Chinese medicine for preventing and treating senile dementias | |
| Garg et al. | Pharmacology of polygala tenuifolia and its significance in traditional Chinese medicine | |
| CN106421447B (en) | A kind of pharmaceutical composition for controlling blood pressure and protecting blood vessel and its production and use | |
| CN102145121A (en) | Chinese medical preparation assisting to adjusting blood sugar | |
| Wagner | Natural products chemistry and phytomedicine research in the new millennium: new developments and challenges | |
| Abdel-Wahhab et al. | Aphrodisiac effects of Panax ginseng extract standardized with ginsenoside Rg3 in male rats | |
| CN109172663B (en) | Pharmaceutical composition for treating anxiety and depression and application thereof | |
| CN103876137A (en) | Health-care traditional Chinese medicine product with function of improving sleep | |
| Tian et al. | Antidepressant-like active ingredients and their related mechanisms of functional foods or medicine and food homologous products | |
| CN103623109B (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| Semalty et al. | Herbal drugs in chronic fatigue syndrome: an overview | |
| Abudunia et al. | In Vivo Potential Anti-inflammatory Activity of Extracts from Calendula Arvensis (CA) Flowers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |